Skip to main content
market.news โ€” Markets without borders
Biotech Sector

Biotech Sector News

Companies developing drugs, therapies, and diagnostics using biological processes.

What is Biotech Sector?

Biotech firms range from early-stage clinical-trial companies (binary outcomes โ€” drugs either work or don't) to large commercial-stage names (Amgen, Gilead, Vertex, Regeneron). Big Pharma (Pfizer, Merck, Novartis, Roche) increasingly acquires biotechs for pipeline. Indian biotech (Biocon) and emerging-market biosimilar makers add global dimension.

Why it matters for investors

Biotech is high-risk, high-reward โ€” successful drug approvals can create multi-bagger returns, while trial failures cause stocks to fall 50%+ overnight. The sector is rate-sensitive (long-duration cash flows) and policy-sensitive (drug pricing, FDA decisions, Medicare negotiations).

Frequently asked questions

How do I evaluate biotech stocks?

For pre-revenue: cash runway, pipeline strength, trial readouts. For commercial: revenue growth, patent cliffs, pipeline-replacement quality.

Why is biotech rate-sensitive?

Drug development has multi-year (often 10+) cash flows. Higher discount rates dramatically reduce present value, hitting biotech valuations harder than mature sectors.

๐ŸŒ Global

AstraZeneca Explored Acquiring Bristol Myers Squibb in Potential Pharma Megadeal

AstraZeneca explored acquiring Bristol Myers Squibb in a deal that would create one of the world's largest drugmakers, per Bloomberg.

Aug 2, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Repligen Lifts Guidance After $1.5B BioLife Acquisition, Valuation Concern Lingers

Repligen acquired BioLife Solutions for $1.5B to add cell therapy capabilities; strong Q2 results lifted guidance but analyst caution points to a stretched valuation.

Aug 2, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Penumbra (PEN) Q2 Revenue Hits $390M Despite Earnings Miss; GF Score 88 Signals Potential Undervaluation

Penumbra (PEN) Q2 revenue of $390M missed earnings estimates, but a GF Score of 88/100 suggests fundamental undervaluation may offer an entry opportunity in the neurovascular medical device sector.

Aug 2, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Eli Lilly's GLP-1 Dominance Drives Surging Stock as Novo Nordisk Trails in Obesity Race

Eli Lilly stock has surged dramatically while Novo Nordisk has fallen sharply as their obesity drug fortunes diverged

Aug 1, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Novo Nordisk Trial Failure Drags Monte Rosa and BioAge Shares Into Sharp Decline

Novo Nordisk's failed heart drug trial triggered a selloff in Monte Rosa (GLUE) and BioAge Labs (BIOA)

Aug 1, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Replimune Surges 127% After FDA Advisory Panel Backs Oncolytic Virus Cancer Therapy

Replimune (REPL) shares jumped 127% after the FDA advisory panel voted in favor of its RP1 oncolytic virus therapy, signaling strong likelihood of full approval

Aug 1, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Replimune Surges 127% Pre-Market as Biotech Rally Meets Valuation Scrutiny

Replimune (REPL) surged 127% pre-market, among the sharpest biotech moves of the session amid broader tech and risk-on sentiment

Aug 1, 2026

๐Ÿ‡ฉ๐Ÿ‡ช Germany

Siemens Healthineers Cuts Revenue Forecast as China Healthcare Reform Crushes Diagnostics Demand

Siemens Healthineers lowered its revenue forecast due to persistent weakness in its diagnostics division, hit by China's hospital procurement reform, adding urgency to the planned unit separation.

Aug 1, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Replimune (REPL) Shares Surge on Positive FDA Advisory Panel Vote for Oncolytic Immunotherapy

Replimune shares surged after FDA advisory committee voted positively on its oncolytic immunotherapy, reducing regulatory risk ahead of the agency's final approval decision.

Aug 1, 2026

๐Ÿ‡ง๐Ÿ‡ท Brazil

DexCom (DXCM) Releases Q2 2026 Earnings Presentation as CGM Leader Navigates Competitive Landscape

DexCom Q2 2026 earnings presentation released as CGM leader navigates GLP-1 headwinds and competitive pressure

Aug 1, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Madrigal and Phathom Both Beat Q2 Revenue Estimates as Specialty Pharma Launches Hold Firm

Madrigal Pharmaceuticals (MDGL) and Phathom Pharmaceuticals (PHAT) both posted Q2 2026 revenue beats, validating commercial execution for Rezdiffra MASH launch and Phathom's acid-suppression pipeline.

Jul 31, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Capricor Therapeutics Shares Plunge 45% After FDA Advisory Panel Vote

Capricor Therapeutics (CAPR) shares collapsed 45% following a negative FDA advisory panel vote on its lead gene therapy candidate, raising approval timeline uncertainty.

Jul 31, 2026

๐Ÿ‡จ๐Ÿ‡ฆ Canada

AbbVie Q2 Beats on Immunology Strength as Botox Shows Revival Signs

AbbVie Q2 profit and sales beat Wall Street estimates driven by immunology and neuroscience franchise strength, with early signs of Botox recovery easing concerns about its aesthetics division plateau.

Jul 31, 2026

๐Ÿ‡ฉ๐Ÿ‡ช Germany

Pharming Group Crashes 20.65% as Q2 Revenue Falls Short of Targets

Pharming Group shares plunged over 20% Thursday after preliminary Q2 results showed significant revenue shortfall

Jul 30, 2026

๐Ÿ‡ฉ๐Ÿ‡ช Germany

UCB Shares Crash 13.9% as Market Punishes Belgian Biopharma Despite H1 Revenue Up 22%

UCB shares fell 13.88% despite H1 revenue rising 22% to โ‚ฌ4.27 billion and management raising guidance

Jul 30, 2026

๐Ÿ‡ฉ๐Ÿ‡ช Germany

Marinomed Biotech Shares Crash 10.71% After Austrian Biotech Files for Court Insolvency

Marinomed Biotech shares fell 10.71% to โ‚ฌ5 after the Austrian biopharma filed for court-supervised insolvency proceedings following financing collapse

Jul 30, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

RPGLS Eyes โ‚น700-1,000 Crore Plant Acquisition to Launch Semaglutide in India

RPGLS plans semaglutide launch in India, investing โ‚น700-1,000 crore for manufacturing facility acquisition

Jul 30, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Synlogic Merger With Caldera Therapeutics Meets Market Skepticism Amid High Valuation

Synlogic (SYBX) is merging with Caldera Therapeutics in a deal that faces investor skepticism

Jul 30, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Bandwidth, uniQure, and Stanley Black & Decker All Miss Q2 Estimates in Diverse Sector Sweep

Bandwidth Inc (BAND) Q2 revenue beat but EPS missed; EBITDA growth signals improving profitability trend

Jul 30, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Anika Therapeutics Q2 Earnings Beat Amid Recovery, GF Score 64 Flags Execution Risk

Anika Therapeutics (ANIK) reported a Q2 2026 earnings beat, signalling potential recovery momentum

Jul 30, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

Apollo Hospitals Pune Performs First Robotic-Assisted CABG Surgery, Advancing Medtech Positioning

Apollo Hospitals' Pune facility performed its first robotic-assisted coronary artery bypass graft (CABG) surgery, marking a technology-capability milestone for India's largest hospital network.

Jul 30, 2026

๐Ÿ‡จ๐Ÿ‡ฆ Canada

Smith+Nephew's TESSA Spatial Surgery System Wins FDA De Novo Classification in Sports Medicine

Smith+Nephew (SNN) received FDA De Novo classification for its TESSA Spatial Surgery System, a significant regulatory milestone.

Jul 29, 2026

Biotech

Altimmune (ALT) Options Surge Points to Speculative Positioning Ahead of Catalyst

Altimmune saw unusual options activity surge, suggesting sophisticated investors may be positioning for a near-term clinical or partnership catalyst.

Jul 29, 2026

Biotech

Replimune (REPL) Plunges 30% After FDA Briefing Raises Concerns on RP1 Melanoma Therapy

Replimune shares plunged 30% after the FDA's pre-advisory briefing raised material concerns about the RP1 melanoma therapy approval pathway.

Jul 29, 2026

Biotech

ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market on Earnings Anticipation

ProMIS Neurosciences surged 21.3% pre-market ahead of earnings as traders priced in biotech optimism.

Jul 29, 2026

๐Ÿ‡ฎ๐Ÿ‡ณ India

AstraZeneca EPS Surges 21% to $2.63 as Oncology Portfolio Beats Estimates

AstraZeneca adjusted EPS climbed 21% to $2.63, comfortably surpassing analyst expectations in the latest quarter

Jul 28, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Gossamer Bio (GOSS) Opens Discussions to Reacquire Rights to Seralutin, Signaling Renewed Pipeline Confidence

Gossamer Bio (NASDAQ: GOSS) disclosed it is in discussions to reacquire rights to seralutin (GB004), a gut-selective S1P1 receptor modulator previously out-licensed

Jul 28, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

Capricor Therapeutics (CAPR) Plunges 67% After FDA Briefing Documents Raise Efficacy Concerns for DMD Cell Therapy

Capricor Therapeutics shares fell 67% after FDA briefing documents ahead of an advisory committee meeting raised significant efficacy concerns for its Duchenne Muscular Dystrophy cell therapy candidate

Jul 28, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

US Equities Surge on Middle East Tension Easing While Forte Biosciences Spikes 39% on Acquisition News

US equity markets posted broad gains as geopolitical risk premia compressed on signs of de-escalation in Middle East conflict

Jul 28, 2026

๐Ÿ‡บ๐Ÿ‡ธ United States

argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio Beyond Vyvgart Into Inflammatory Dermatology

argenx SE (ARGX) agreed to acquire Forte Biosciences (FBRX) for approximately $2.2 billion, expanding its immunology pipeline into inflammatory skin disease treatments

Jul 28, 2026